We are developing an innovative cell therapy pipeline with the potential to redefine standards of care across a range of conditions where there is an urgent medical need. 

​

We are applying our proprietary cardiac cell technology to treat several conditions caused by underlying ischemic injury potentially, including but not limited to Heart Failure, Myocardial Ischemia, Coronary Microvascular Dysfunction (CMD), Critical Limb Ischemia (CLI), Heart Failure with Reduced Ejection Fraction and No-Option Refractory Disabling Angina (NORDA). These indications represent major areas of clinical need and substantial commercial opportunities. 

​

Explore our pipeline below for information on our clinical development candidates.